ClinicalTrials.Veeva

Menu

Study of an Approved Drug in Patients With Asthma (0476-289)(COMPLETED)

Organon logo

Organon

Status and phase

Completed
Phase 3

Conditions

Asthma

Treatments

Drug: Comparator: placebo / Duration of Treatment: 4 weeks
Drug: MK0476, montelukast sodium / Duration of Treatment: 4 weeks

Study type

Interventional

Funder types

Industry

Identifiers

NCT00092144
2004_028
0476-289

Details and patient eligibility

About

The purpose of this study is to assess the efficacy and safety of an approved drug on asthma symptoms in patients with chronic asthma which is also active during the allergy season.

Enrollment

500 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Asthma symptoms brought on by allergies

Exclusion criteria

  • Patient has any lung disease
  • Currently have a sinus infection or cold symptoms

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems